

**Science Advisory Board (SAB)
Open Meeting, October 27-28, 1999
Holiday Inn Georgetown,
2101 Wisconsin Ave., NW, Washington, DC 20007
202-338-4600**

Review of EPA's Draft Chloroform Risk Assessment

WEDNESDAY, October 27, 1999

- 9:00 AM Introduction - Drs. Richard Bull and Mark Utell (Co-Chairs)
- 9:10 AM Administrative Procedures, Member/Consultant Introductions, and report preparation discussion- Mr. Samuel Rondberg and Mr. Thomas Miller (Co-Designated Federal Officials)
- 9:40 AM EPA briefing on background and major issues for this review:
- Ephraim King, Acting Director, Standards and Risk Management Division, Office of Groundwater and Drinking Water, Office of Water: The Disinfection/Disinfection Byproducts Rule
- Jeanette Wiltse, Ph.D., Director, Health and Ecological Criteria Division, Office of Science and Technology, Office of Water: Chloroform Assessment Process and Charge for this review
- 10:10 AM Break
- 10:25 AM Vicki Dellarco, Ph.D., Senior Geneticist, Health Effects Division, Office of Pesticide Program: Chloroform--Mode of Carcinogenic Action
- 11:15 AM Public Comment
- Dr. Jay Goodman (Michigan State University) on behalf of the ILSI
Dr. David Wallinga, Natural Resources Defense Council
Dr Robert Tardiff on behalf of the Chlorine Chemistry Council
Dr. Byron E. Butterworth, CIIT
Dr. Robert Golden, ToxLogic
- 12:05 Noon Lunch
- 1:15 PM Issue 1: Based on its application to the chloroform risk assessment, please

identify any specific text in the draft Cancer Risk Assessment Guideline's framework for mode of action analysis (section 2.5) which you would advise be changed prior to their publication.

Subcommittee Members

3:15 PM Break

3:30 PM Issue a(i) Chloroform's mode of action
Dr. Maronpot Lead; Dr. Klaunig, Associate

4:15 PM Issue a(ii) Consideration of a nonlinear approach to dose-response, and the possibility that mutagenesis might play a role in the carcinogenic response.
Dr. Zeise Lead; Dr. Ray, Associate

NB—the following issue is taken out of numerical order to accommodate Member's schedules

5:00 PM Issue a(iv) Epidemiologic evidence on chlorinated drinking water as to the carcinogenicity of chloroform, including comment on any conclusion to be drawn from the epidemiologic data about mode of action.
Dr. Savitz, Lead; Drs. Zeise and Bull, Associates

5:45 PM Adjourn

THURSDAY, October 28, 1999

9:00 AM Issue a(iii) The relationship of low-dose pathology to the doses that induce tumors.
Dr. Klaunig, Lead; Dr. Maronpot, Associate

9:45 AM Issue b Does the assessment of children's risk for chloroform appropriately address the risk concerns (including ontogeny of drug metabolizing enzymes), given the data available?
Dr. Lambert, Lead; Drs. Davis and Okita, Associates

10:15 AM Break

10:45 AM Return to consideration of Issue 1—suggested changes to section 2.5 of the Cancer Risk Assessment Guidelines/content of "brief" report
Subcommittee

12:00 Noon Adjourn